Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Abou Alaiwi S, Roston TM, Marstrand P, Claggett BL, Parikh VN, Helms AS, et al.  

Sex-Specific Clinical and Genetic Factors Associated with Adverse Outcomes in Hypertrophic Cardiomyopathy. Butters A, Arnott C, Sweeting J, Claggett B, Cuomo A, Abrams D, et al.

Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al.

New York Heart Association Functional Class And Mortality In Obstructive Hypertrophic Cardiomyopathy. Lakdawala N, Saberi S, Day S, Ingles J, Semsarian C, Olivotto I, et al.

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al.

Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. Nauffal V, Marstrand P, Han L, Parikh VN, Helms AS, Ingles J, et al.

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Thompson AD, Helms AS, Kannan A, Yob J, Lakdawala NK, Wittekind SG, et al.

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, et al.

Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Lakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, et al.

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Helms AS, Thompson AD, Glazier AA, Hafeez N, Kabani S, Rodriguez J, et al.

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry. Canepa M, Fumagalli C, Tini G, Vincent-Tompkins J, Day SM, Ashley EA, et al.

A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Miron A, Lafreniere-Roula M, Steve Fan CP, Armstrong KR, Dragulescu A, Papaz T, et al.

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels ME, et al.

Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. Fumagalli C, Maurizi N, Day SM, Ashley EA, Michels M, Colan SD, et al.

Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, et al.

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al.

Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Lee SP, Ashley EA, Homburger J, Caleshu C, Green EM, Jacoby D, et al.

Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. Furqan A, Arscott P, Girolami F, Cirino AL, Michels M, Day SM, et al.

Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation. Homburger JR, Green EM, Caleshu C, Sunitha MS, Taylor RE, Ruppel KM, et al.